Philip Morris International sells nicotine products to adult consumers in roughly 170 markets around the world. It makes money the same way every day: people use up cigarettes, heated tobacco sticks, and nicotine pouches, then buy more. The company's biggest cigarette brand is Marlboro, but its fastest-growing products are smoke-free ones: IQOS heated tobacco devices and their refill sticks, ZYN nicotine pouches, and VEEV e-vapor products. Cigarettes still generate most of the volume, but smoke-free products are growing fast enough that the company has reorganized itself around them. The diagram below traces where the money goes.
How Philip Morris International Makes Money
flowchart TD
A["Tobacco Leaf & Materials
Procurement"] --> B["Manufacturing:
Cigarettes & Smoke-Free
607.4B cigarettes, 179.1B SFP units"]
B --> C["Combustible Products
$23.8B revenue"]
B --> D["Smoke-Free Products
IQOS, ZYN, VEEV
$16.9B revenue"]
C --> E["Total Revenue
$40.6B"]
D --> E
E --> F["Operating Income
36.6% margin
$14.9B"]
F --> G["R&D & Brand Investment
$16B total since 2008"]
G --> D
E --> H["Free Cash Flow
$10.7B"]
H --> I["Dividends &
Debt Service"]
I --> A
H --> G
C --> J["170 Markets
Distribution Network"]
D --> J
J --> E
Five years of financial data tell a clear story about direction. Revenue has climbed every single year, from $31.4 billion in 2021 to $40.6 billion in 2025. That is a consistent upward line, not a flat or lumpy one. The growth is real, not just inflation: smoke-free product shipments grew 12.8% in 2025 alone, while cigarette shipments fell 1.5%. The business is literally replacing one product with another in real time.
Net Revenue 2021 to 2025 (USD billions)
Revenue has grown every year for five consecutive years, rising from $31.4B to $40.6B.
The profit side of the ledger needs more careful reading. Gross margin dipped from 68.1% in 2021 to a low of 63.3% in 2023, then recovered to 67.1% by 2025. That dip lines up with the $16 billion the company has spent since 2008 building out smoke-free products, plus the cost of absorbing Swedish Match, which it acquired in late 2022. Free cash flow tells a similar story: it dropped from $11.2 billion in 2021 to $7.9 billion in 2023, then bounced back to $10.7 billion in 2025. The pressure was real, and the recovery appears real too.
$40.4B
Net debt at end of 2025, up from $20.5B in 2021, largely due to the Swedish Match acquisition
The debt load is the one number that demands attention. Net debt doubled from $20.5 billion in 2021 to $40.4 billion by 2025. Most of that jump came from borrowing to buy Swedish Match in 2022, which added ZYN to the portfolio. ZYN is now one of the fastest-growing nicotine products in the United States. Whether that acquisition was worth doubling the debt load depends entirely on how fast ZYN and IQOS keep growing.
2022
milestone
Swedish Match acquisition adds ZYN to the portfolio
In November 2022, PMI acquired Swedish Match for roughly $16 billion. This brought ZYN nicotine pouches into the company, gave PMI a strong position in oral smoke-free products, and added meaningful U.S. revenue. It also roughly doubled net debt. The deal reset the financial structure of the entire company.
The risks the company itself names are specific and serious. Regulators anywhere in its 170 markets could restrict or ban smoke-free products, or block the company from telling consumers what the science says about them. That would cut the legs off the entire growth strategy. In the United States specifically, the Food and Drug Administration (FDA) could withdraw its authorizations for IQOS or ZYN. Those authorizations are rare and were hard won. Losing them would be a major blow.
What FDA authorization means for smoke-free products
The FDA has to approve tobacco and nicotine products before they can be marketed in the United States. PMI's IQOS devices and ZYN nicotine pouches have received two kinds of approval: a basic marketing authorization, and a harder-to-get Modified Risk Tobacco Product (MRTP) authorization. The MRTP label allows the company to tell consumers the product presents less risk than continued smoking. No other products in their categories have ever received these authorizations. If the FDA revokes them, PMI loses both the right to sell and the right to make those claims.
There is also a single-factory risk that is easy to overlook. Almost all ZYN pouches sold in the United States come from one facility in Kentucky. A fire, a cyberattack, or a disease outbreak at that one building could stop ZYN sales in the country's biggest market with no quick backup plan. That is an unusual concentration of operational risk for a product that is supposed to drive years of growth.
~9%
Share of cigarette and heated tobacco sales that come from Russia, a market exposed to asset seizure and currency controls due to the war in Ukraine
Russia adds geopolitical weight to the risk picture. The country accounts for roughly 9% of cigarette and heated tobacco unit sales and about 6% of total revenue. The war in Ukraine means the Russian government could seize assets, ban operations, or prevent the company from moving money out. PMI already experienced a taste of this when Russian forced localization rules disrupted its distributor arrangement in 2024 and triggered a $77 million tax charge.
What 'forced localization' means in Russia
Russia passed laws allowing the government to force foreign-owned companies out of the ownership structure of businesses operating in Russia. In 2024, PMI's Russian distributor, Megapolis, was subjected to this process. Shares owned through a foreign holding company were transferred away without PMI's consent. This is a preview of the kind of asset risk that exists in that market.
Smoke-free products now represent a large and growing share of revenue, but they are also harder to forecast than cigarettes. Consumer preferences for new products can shift suddenly. Competitors are launching their own heated tobacco and pouch products. Some of them may be cutting corners on regulation or science, which could damage the reputation of the whole category. PMI has spent over $16 billion since 2008 trying to build a scientifically credible smoke-free business. A competitor who ignores those standards could undercut prices while PMI carries the cost of doing things properly.
+12.8%
Smoke-free product shipments growth in 2025
-1.5%
Cigarette shipments change in 2025
The two halves of the business are moving in opposite directions at the same time.
PMI reorganized its entire reporting structure in early 2026, replacing four geographic segments with three product-focused ones: International Smoke-Free, International Combustibles, and U.S. That is not a cosmetic change. It signals that management now thinks of the business as two products in transition, not four regions.
The Bet
PMI's smoke-free products, led by IQOS and ZYN, continue growing fast enough and profitably enough to replace the revenue and cash flow that cigarettes will gradually give up over time. If regulators allow smoke-free products to be marketed freely, and if enough adult smokers switch to them rather than quitting nicotine altogether, the transition works and the debt taken on to build it gets paid down from growing smoke-free cash flows. If regulators tighten restrictions, or if smokers simply quit rather than switch, the growth engine stalls while the $40.4 billion debt load stays.
Open question
PMI has built a real and growing smoke-free business. Revenue is up, margins have recovered, and products like IQOS and ZYN have genuine regulatory approvals that competitors lack. But the company is carrying twice the debt it had four years ago, nearly all of its U.S. ZYN supply runs through one building in Kentucky, and about 6% of total revenue sits in a country where asset seizure is now a documented risk. Can IQOS and ZYN grow fast enough, in enough markets, with enough regulatory stability, to justify a $40.4 billion debt load and fund a full transition away from cigarettes before the headwinds from regulation, competition, and geopolitics catch up?
[1]
PMI 10-K 2025, Item 1 Business Description
[2]
PMI 10-K 2025, Item 7 MD&A
[3]
PMI 10-K 2025, Item 1A Risk Factors
[4]
PMI XBRL financials 2021 to 2025
Compiled · 10-K · FY2025
